Supportive Care in Cancer

, 14:890 | Cite as

Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies

  • Rachel J. Gibson
  • Dorothy M. K. Keefe
Review Article



Diarrhoea and constipation are common toxicities of chemotherapy, and both are poorly understood. They are manifestations of alimentary mucositis, a condition which affects the entire gastrointestinal tract.


The absolute percentage of patients that have diarrhoea or constipation as a result of their treatment has yet to be fully defined, although general estimates place 10% of patients with advanced cancer as being afflicted. Although there has been some major progress in recent years with understanding the mechanisms of oral and small intestinal mucositis, diarrhoea and constipation have received very little attention. Although diarrhoea is a well-recognised side-effect of both chemotherapy and radiotherapy, very little research has been conducted on the mechanisms behind diarrhoea or its treatment. Much of the information in the published literature is based on clinical observations with very little basic science existing. Constipation is not as well recognised and very little is known about its mechanisms.


This review will examine in detail the potentially complex pathogenesis of post-chemotherapy diarrhoea in both animal models and the clinical setting. Furthermore, it will explore what is known about chemotherapy-induced constipation. It will then outline an evidence-based pathway for the investigation and treatment of post-chemotherapy diarrhoea and constipation.


Diarrhoea Constipation Mucositis Chemotherapy 


  1. 1.
    Abigerges D, Armand JP, Chabot GG, DaCosta L, Fadel E, Cote C, Heraot P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhoea. J Natl Cancer Inst 86:446–449PubMedCrossRefGoogle Scholar
  2. 2.
    Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A (2003) Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805–806CrossRefPubMedGoogle Scholar
  3. 3.
    Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M (2004) New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 30:555–562CrossRefPubMedGoogle Scholar
  4. 4.
    Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhaea and the concentration of SN-38, and active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697–702PubMedGoogle Scholar
  5. 5.
    Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O’Dorisio TM, Vokes EE, Wadler S (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918–2926CrossRefPubMedGoogle Scholar
  6. 6.
    Campbell T, Draper S, Reid J, Robinson L (2001) The management of constipation in people with advanced cancer. Int J Palliat Nurs 7:110–119PubMedGoogle Scholar
  7. 7.
    Cao S, Rustum YM (2000) Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60:3717–3721PubMedGoogle Scholar
  8. 8.
    Cao S, Rustum YM, Spector T (1994) 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507–1510PubMedGoogle Scholar
  9. 9.
    Cao S, Frank C, Rustum YM (1996) Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma. J Natl Cancer Inst 88:430–436PubMedCrossRefGoogle Scholar
  10. 10.
    Cao S, Black JD, Troutt AB, Rustum YM (1998) Interleukin 15 offers selective protection from Irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58:3270–3274PubMedGoogle Scholar
  11. 11.
    Cao S, Troutt AB, Rustum YM (1998) Interleukin 15 protects against toxicity and potentiates against antitumor activity of 5-flououracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res 58:1695–1699PubMedGoogle Scholar
  12. 12.
    Carpenter CCJ (1982) The pathophysiology of secretory diarrheas. Med Clin North Am 66:597–610PubMedGoogle Scholar
  13. 13.
    Cascinu S (1995) Drug therapy in diarrheal diseases in oncology/hematology patients. Crit Rev Oncol Hematol 18:37–50PubMedCrossRefGoogle Scholar
  14. 14.
    Cascinu S, Fedeli A, Fedeli SL, Catalano G (1992) Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 28:482–3CrossRefPubMedGoogle Scholar
  15. 15.
    Castro-Rodriguez JA, Salazar-Lindo E, Leon-Barua R (1997) Differentiation of osmotic and secretory diarrhoea by stool carbohydrate and osmolar gap measurements. Arch Dis Child 77:201–205PubMedGoogle Scholar
  16. 16.
    de Roy van Zuidewijn DB, Schillings PH, Wobbes T, Hendriks T, de Boer HH (1992) Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Exp Mol Pathol 56:96–107CrossRefPubMedGoogle Scholar
  17. 17.
    Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367CrossRefPubMedGoogle Scholar
  18. 18.
    Engelking C, Rutledge DN, Ippoliti C, Neumann J, Hogan CM (1998) Cancer-related diarrhea: a neglected cause of cancer-related symptom distress. Oncol Nurs Forum 25:859–860PubMedGoogle Scholar
  19. 19.
    Fittkau M, Voigt W, Holzhausen HJ, Schmoll HJ (2004) Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J Cancer Res Clin Oncol 130:388–394CrossRefPubMedGoogle Scholar
  20. 20.
    Gall LS (1970) Normal fecal flora of man. Am J Clin Nutr 23:1457–1465PubMedGoogle Scholar
  21. 21.
    Gelfand MD, Tepper M, Katz LA, Binder HJ, Yesner R, Floch MH (1968) Acute irradiation proctitis in man: development of eosinophilic crypt abscesses. Gastroenterology 54:401–11PubMedGoogle Scholar
  22. 22.
    Gibson RJ, Keefe DMK, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BE, Cummins AG (2002) The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50:53–58CrossRefPubMedGoogle Scholar
  23. 23.
    Gibson RJ, Keefe DMK, Thompson FM, Clarke JM, Goland GJ, Cummins AG (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751–2757CrossRefPubMedGoogle Scholar
  24. 24.
    Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DMK (2003) Irinotecan causes severe small intestinal damage as well as colonic damage in the rat with implanted breast cancer. J Gastroenterol Hepatol 18:1095–1100CrossRefPubMedGoogle Scholar
  25. 25.
    Ginopoulos P, Papagiannis T, Safridi C, Karvelas F, Spyropoulos K, Papadas T, Gogos C (1996) Octreotide treatment of chemotherapy-induced diarrhoea. Eur J Cancer 32A:182–183CrossRefPubMedGoogle Scholar
  26. 26.
    Gorbach SL, Banwell JG, Chatterjee BD, Jacobs B, Sack RB (1971) Acute undifferentiated human diarrhea in the tropics: I: Alterations in intestinal microflora. J Clin Invest 50:881–889PubMedCrossRefGoogle Scholar
  27. 27.
    Gosselink MP, Schouten WR, van Lieshout LMC, Hop WCJ, Laman JD, Ruseler-van Embden JGH (2004) Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciproffloxacin in the treatment of pouchitis. Dis Colon Rectum 47:1519–1525CrossRefPubMedGoogle Scholar
  28. 28.
    Gutheil JC, Kearns CM (1997) Antimetabolites. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, MD, pp 317–344Google Scholar
  29. 29.
    Gwede CK (2003) Overview of radiation- and chemoradiation-induced diarrhea. Semin Oncol Nurs 19:6–10CrossRefPubMedGoogle Scholar
  30. 30.
    Haenel H (1970) Human normal and abnormal gastrointestinal flora. Am J Clin Nutr 23:1433–1439PubMedGoogle Scholar
  31. 31.
    Hogan CM (1998) The nurse’s role in diarrhea management. Oncol Nurs Forum 25:879–886PubMedGoogle Scholar
  32. 32.
    Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic changes in the mouse ileum and cecum. J Natl Cancer Inst 87:1876–1883PubMedCrossRefGoogle Scholar
  33. 33.
    Ippoliti C, Neumann J (1998) Octreotide in the management of diarrhea induced by graft versus host disease. Oncol Nurs Forum 25:873–878PubMedGoogle Scholar
  34. 34.
    Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR (2001) Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 24:353–367CrossRefPubMedGoogle Scholar
  35. 35.
    Jenkins D, Balsitis M, Gallivan S, Dixon MF, Gilmour HM, Shepherd NA, Theodossi A, Williams GT (1997) Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. Br Soc Gastroenterol Int J Clin Pathol 50:93–105Google Scholar
  36. 36.
    Keefe DMK (1998) The effect of cytotoxic chemotherapy on the mucosa of the small intestine. Department of Medicine, University of Adelaide, AdelaideGoogle Scholar
  37. 37.
    Keefe DM (2004) Gastrointestinal mucositis: a new biological model. Support Care Cancer 12:6–9CrossRefPubMedGoogle Scholar
  38. 38.
    Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE (1997) Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci 92:385–389PubMedGoogle Scholar
  39. 39.
    Keefe DM, Brealey J, Goland GJ, Cummins AG (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47:632–637CrossRefPubMedGoogle Scholar
  40. 40.
    Keefe DM, Gibson RJ, Hauer-Jenson M (2004) Gastrointestinal mucositis. Semin Oncol Nurs 20:38–47CrossRefPubMedGoogle Scholar
  41. 41.
    Klainer AS, Gorbach SL, Weinstein L (1967) Studies of intestinal microflora. VI: Effect of X irradiation on the fecal microflora of the rat. J Bacteriol 92:378–382Google Scholar
  42. 42.
    Klainer AS, Gorbach SL, Weinstein L (1967) Studies of intestinal microflora: VII: Effect of diet and fecal microbial flora on survival of animals exposed to X irradiation. J Bacteriol 94:383–387PubMedGoogle Scholar
  43. 43.
    Kofteridis DP, Maraki S, Mixaki I, Mantadakis E, Samonis G (2004) Impact of prolonged treatment with trimethoprim-sulfamethoxazole on the human gut flora. Scand J Infect Dis 36:771–772PubMedGoogle Scholar
  44. 44.
    Leiper K, Campbell BJ, Jenkinson MD, Milton J, Yu LG, Democratis J, Rhodes JM (2001) Interaction between bacterial peptides, neutrophils and goblet cells: a possible mechanism for neutrophil recruitment and goblet cell depletion in colitis. Clin Sci (Lond) 101:395–402CrossRefGoogle Scholar
  45. 45.
    Li L-J, Wu Z-W, Xiao D-S, Sheng J-F (2004) Changes of gut flora and endotoxin in rats with d-galactosamine-induced acute liver failure. World J Gastroenterol 10:2087–2090PubMedGoogle Scholar
  46. 46.
    Ma MK, McLeod HL (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10:41–49CrossRefPubMedGoogle Scholar
  47. 47.
    Macdonald DR (1997) Neurotoxicity of chemotherapeutic agents. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, MD, pp 745–766Google Scholar
  48. 48.
    Mancini I, Bruera E (1998) Constipation in advanced cancer patients. Support Care Cancer 6:356–364CrossRefPubMedGoogle Scholar
  49. 49.
    McCormick DA, Horton LW, Mee AS (1990) Mucin depletion in inflammatory bowel disease. J Clin Pathol 43:143–6PubMedCrossRefGoogle Scholar
  50. 50.
    Mercadante S (1995) Diarrhea in terminally ill patients: pathophysiology and treatment. J Pain Symptom Manage 10:298–308CrossRefPubMedGoogle Scholar
  51. 51.
    Milles SS, Muggia AL, Spiro HM (1962) Colonic histologic changes induced by 5-fluououracil. Gastroenterology 43:391–399Google Scholar
  52. 52.
    Nostrant TT, Kumar NB, Appelman HD (1987) Histopathology differentiates acute self-limited colitis from ulcerative colitis. Gastroenterology 92:318–328PubMedGoogle Scholar
  53. 53.
    Pico J-L, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3:446–451PubMedGoogle Scholar
  54. 54.
    Portenoy R (1987) Constipation in the cancer patient: causes and management. Med Clin North Am 71:303–310PubMedGoogle Scholar
  55. 55.
    Read NW, Timms JM (1986) Defecation and the pathophysiology of constipation. Clin Gastroenterol 15:937–965PubMedGoogle Scholar
  56. 56.
    Reinecker HC, MacDermott RP, Mirau S, Dignass A, Podolsky DK (1996) Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology 111:1706–1713CrossRefPubMedGoogle Scholar
  57. 57.
    Rubenstein EB, Peterson DE, Schubert MM, Keefe DM, McGuire DB, Epstein JB, Elting LS, Fox PC, Loprinzi CL, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMedGoogle Scholar
  58. 58.
    Rutledge DN, Engelking C (1998) Cancer-related diarrhea: selected findings of a national survey of oncology nurse experiences. Oncol Nurs Forum 25:861–873PubMedGoogle Scholar
  59. 59.
    Saltz LB (2003) Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 1:35–46; discussion 38–41, 45–6PubMedGoogle Scholar
  60. 60.
    Saltz L, Shimada Y, Khayat D (1996) CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 32A(Suppl 3):S24–S31CrossRefPubMedGoogle Scholar
  61. 61.
    Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6:93–102CrossRefPubMedGoogle Scholar
  62. 62.
    Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ (1998) Prevention of intestinal toxic effects and intensification of Irinotecan’s therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Clin Cancer Res 4:2053–2063PubMedGoogle Scholar
  63. 63.
    Shinohara H, Killion JJ, Bucana CD, Yano S, Fidler IJ (1999) Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin Cancer Res 5:2148–2156PubMedGoogle Scholar
  64. 64.
    Si J-M, Yu Y-C, Fan Y-J, Chen S-J (2004) Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 10:1802–1805PubMedGoogle Scholar
  65. 65.
    Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43CrossRefPubMedGoogle Scholar
  66. 66.
    Sonis ST, Tracey C, Shklar G, Jenson J, Florine D (1990) An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69:437–443PubMedCrossRefGoogle Scholar
  67. 67.
    Sonis ST, Costa JW, Jr, Evitts SM, Lindquist LE, Nicolson M (1992) Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 74:749–755CrossRefPubMedGoogle Scholar
  68. 68.
    Sonis ST, Van Vugt AG, Brien JP, Muska AD, Bruskin AM, Rose A, Haley JD (1997) Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 33:47–54PubMedCrossRefGoogle Scholar
  69. 69.
    Sonis S, Edwards L, Lucey C (1999) The biological basis for the attenuation of mucositis: the example of interleukin-11. Leukemia 13:831–834CrossRefPubMedGoogle Scholar
  70. 70.
    Sonis ST, Elting LS, Keefe DM, Peterson DE, Schubert MM, Hauer-Jenson M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein E (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMedGoogle Scholar
  71. 71.
    Stern J, Ippoliti C (2003) Management of acute cancer treatment-induced diarrhea. Semin Oncol Nurs 19:11–16CrossRefPubMedGoogle Scholar
  72. 72.
    Sykes NP (1994) Current approaches to the management of constipation. Cancer Surv 21:137–146PubMedGoogle Scholar
  73. 73.
    Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752–3757PubMedGoogle Scholar
  74. 74.
    Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280–286CrossRefPubMedGoogle Scholar
  75. 75.
    Talley NJ (2004) Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Dis 4:S3–S10CrossRefGoogle Scholar
  76. 76.
    Viele CS (2003) Overview of chemotherapy-induced diarrhea. Semin Oncol Nurs 19:2–5CrossRefPubMedGoogle Scholar
  77. 77.
    Wadler S, Benson AB, 3rd, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16:3169–3178PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Medical OncologyRoyal Adelaide HospitalAdelaideAustralia
  2. 2.Department of MedicineUniversity of AdelaideAdelaideAustralia

Personalised recommendations